Patent ID: 8992951
Filing Date: 2015-03-31
Classification: A61K,A61P,Y02A

Abstract:
1. A formulation adapted for the prophylactic treatment of neuropathology caused by trauma to a subject, or for the amelioration of the effects caused by trauma to a subject, the formulation comprising at least one compound of each of A, B, C, and D below, in amounts that are pharmaceutically effective for each compound, respectively, when administered in combination with the other compounds, the formulation comprising a pharmaceutically effective amount of: A) at least one compound from the group comprising anticonvulsants and antiepileptics, wherein the compound is one or more of gabapentin, pregabalin and valproic acid, wherein, when gabapentin is included in the formulation, it is provided in a dosage range of from about 5.0 mg to about 9,600 mg; wherein when pregabalin is included in the formulation, it is provided in a dosage range of from about 0.5 mg to about 2,400 mg, and wherein when valproic acid is included in the formulation, it is provided in a dosage range of from about 25 mg to about 8,400 mg; B) at least one compound from the group comprising neurosteroids, neuroactive steroids and progestins, wherein the compound comprises methylprednisolone and optionally one or more of megestrol acetate and ganaxolone, wherein, the methylprednisolone is included in the formulation in a dosage range of from about 0.02 mg to 500 mg; C) at least one compound from the group comprising NK-1 receptor antagonists, wherein the compound comprises aprepitant and optionally one or more of vestipitant and casopitant, wherein, the aprepitant is included in the formulation in a dosage range of from about 0.05 mg to about 750 mg, when vestipitant is included in the formulation, it is provided in a dosage range of from about 0.001 mg to about 200 mg, and when casopitant is included in the formulation, it is provided in a dosage range of from about 0.005 mg to about 1,000 mg; and D) at least one compound from the group comprising lithium-containing compounds, wherein the lithium-containing compound is one or more of lithium carbonate, lithium citrate and lithium chloride, and wherein, when lithium carbonate is included in the formulation, it is provided in a dosage range of from about 0.5 mg to about 3,600 mg, when lithium citrate is included in the formulation, it is provided in a dosage range of from about 0.01 mg to about 2,400 mg, and when lithium chloride is included in the formulation, it is provided in a dosage range of from about 3 mg to about 3,600 mg, wherein the formulation is in a form and a dosage with respect to each of its components such that it is adapted and arranged for administration to a mammal in need thereof, such that the development, or the risk of development, of neuropathology caused by trauma to a subject, or for the effects caused by trauma to a subject, are reduced, lessened, attenuated or prophylactically treated, and wherein the formulation is provided in a single dosage unit.